We are conducting a study to evaluate an intranasal study drug, INNA-051.

Respiratory viral infections are amongst the most common causes of morbidity worldwide and are associated with severe health consequences for a broad range of age groups and demographics. INNA-051 is being tested as a new potential treatment for common respiratory viruses like SARS-CoV-2 (the coronavirus that causes COVID-19) influenza (the flu), respiratory syncytial virus (RSV), and others. 

To be eligible for this study you must:

• Be a generally healthy male or female
• Aged between 18 to 45 years old
• Must have a BMI of between 18 to 34.9kg/m²
• Have a body weight of 50kg or greater

If eligible, you will be required to stay for 10 nights in our facility at Randwick in Sydney, NSW. You will also need to accept 1 follow-up phone call after you are discharged.

If you meet the criteria for this study and would like more information, please register using the button below or call/email our Recruitment Team on 1800 727 874 or email us at recruitment@scientiaclinicalresearch.com.au